“…In this case, the result was related to the higher cost of ertapenem, a carbapenem used on an outpatient basis as compared with meropenem, used for hospitalized patients. 10,13 Another study with 39 patients designed specifically to evaluate the cost-utility of OPAT for SUS, however, showed that this treatment modality was effective in this regard by allowing overall savings of 31.86% from the hospital perspective and 26.53% from the SUS perspective, with favorable clinical outcomes and perception of quality of life. 14 Regarding OPAT in PHI, two other studies were published.…”